Ocular Inflammation Treatment Market Report, Global, 2024

The ocular inflammation treatment market size has grown strongly in recent years. It will grow from $8.85 billion in 2023 to $9.38 billion in 2024 at a compound annual growth rate (CAGR) of 6%. The growth observed during the historic period can be attributed to several factors, including advancements in ophthalmic research, an increased incidence of ocular inflammatory conditions, a growing aging population, the expansion of healthcare infrastructure, rising awareness about eye health, innovation in treatment modalities, and the development of novel therapeutics.

The ocular inflammation treatment market size is expected to see strong growth in the next few years. It will grow to $11.88 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The anticipated growth in the forecast period can be attributed to several factors, including the rising demand for biologics and targeted therapies, an emphasis on early diagnosis and intervention, increasing healthcare expenditure, expanding access to ophthalmic care, growing adoption of teleophthalmology solutions, and regulatory support for novel treatments. Major trends expected in the forecast period include a shift towards biologic therapies, advancements in drug delivery, personalized medicine approaches, integration of teleophthalmology, regulatory emphasis on safety and efficacy, and expansion of therapeutic options.

The increasing proportion of elderly individuals is anticipated to stimulate growth in the ocular inflammation treatment market. Aging, a natural process characterized by gradual physiological decline and tissue integrity loss, is on the rise due to factors such as improved healthcare, declining birth rates, and increased life expectancy. As the aging population expands, the demand for ocular inflammation treatment rises to manage and safeguard vision against age-related inflammation-related conditions. For instance, a report from the World Health Organization projected a significant increase in the demographic of individuals aged 60 and above, from 1 billion in 2020 to 1.4 billion by 2022, with estimates suggesting that one out of every six individuals globally will be aged 60 or older by 2030. Consequently, the aging population's growth will propel the ocular inflammation treatment market.

Prominent players in the ocular inflammation treatment sector are concentrating on integrating advanced technologies, such as self-emulsifying drug delivery system (SEDDS) technology, into eye drops. This integration aims to enhance drug absorption, extend therapeutic effects, and improve patient convenience. SEDDS technology in eye drops enhances bioavailability and ocular absorption of therapeutic agents, promising more effective treatment outcomes for various ocular conditions. For example, ENTOD Pharmaceuticals launched CYCLOTEARS eye drops in May 2023, targeting patients with inflammatory dry eye disease, a prevalent condition. CYCLOTEARS stands out as the world's first dry eye therapy to feature the company's proprietary SEDDS technology, developed by Indian scientists endorsed by the Department of Scientific and Industrial Research (DSIR). Collaborations with esteemed eye research institutes across India have been instrumental in the technology's development.

In June 2023, Bausch + Lomb acquired eye care products from Novartis AG for $1.75 billion, strategically strengthening its presence in the dry eye disease market segment. This acquisition, featuring Xiidra as a key asset, enhances Bausch + Lomb's ability to address the prevalent condition affecting millions globally. Novartis AG, a Swiss pharmaceutical corporation, specializes in producing drugs for ocular inflammation treatment.

Major companies operating in the ocular inflammation treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Bristol Myers Squibb Company, Alcon Laboratories Inc., Bausch Health Companies Inc., Macleods Pharmaceuticals Ltd, Intas Pharmaceuticals Ltd, Cipla Inc., Santen Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals, Akron Pharma Inc, Sun Pharmaceutical Industries Ltd., Alimera Sciences, Ocular Therapeutix Inc., EyePoint Pharmaceuticals Inc., Tarsier Pharma, Graybug Vision Inc., EyeGate, Oculis S.A.

North America was the largest region in the ocular inflammation treatment market in 2023. The regions covered in the ocular inflammation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ocular inflammation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ocular inflammation treatment involves medical interventions aimed at reducing swelling and safeguarding the eyes from damage caused by inflammation, ensuring clear vision and eye health. Typically, treatment for ocular inflammation encompasses medication, eye drops, and occasionally additional therapies, tailored to the severity and underlying cause of the inflammation.

The primary types of ocular inflammation treatment include immunosuppressants, antivirals, corticosteroids, antibiotics, analgesics, monoclonal antibodies, antifungals, and cycloplegics. Immunosuppressants are medications designed to diminish the activity of the body's immune system, thereby aiding in controlling inflammation in the eyes. These treatment modalities are administered via injectables, orals, topicals, and other routes, targeting disease types such as anterior uveitis, intermediate uveitis, episcleritis/scleritis, posterior uveitis, and panuveitis. The distribution channels for these treatment products include retail pharmacies, online pharmacies, hospital pharmacies, and drug stores.

The ocular inflammation treatment market research report is one of a series of new reports that provides ocular inflammation treatment market statistics, including ocular inflammation treatment industry global market size, regional shares, competitors with a ocular inflammation treatment market share, detailed ocular inflammation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the ocular inflammation treatment industry. This ocular inflammation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ocular inflammation treatment market consists of revenues earned by entities by providing services such as diagnostic services, treatment administration services, patient support programs, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ocular inflammation treatment market also includes sales of long-acting corticosteroid implants, contact lenses, compounded medications, and biodegradable inserts. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.